This company listing is no longer active
Resumen de acción S1BA
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 3 riesgos adicionales
Competidores de Stealth BioTherapeutics Corp
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | €0.27 |
| 52 Week High | €0.80 |
| 52 Week Low | €0.17 |
| Beta | 1.46 |
| 1 Month Change | -2.90% |
| 3 Month Change | -18.29% |
| 1 Year Change | -67.71% |
| 3 Year Change | -96.03% |
| 5 Year Change | n/a |
| Change since IPO | -97.95% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| S1BA | DE Biotechs | Mercado DE | |
|---|---|---|---|
| 7D | -0.7% | 2.6% | 0.9% |
| 1Y | -67.7% | -20.6% | 4.7% |
Rentabilidad vs. Industria: S1BA underperformed the German Biotechs industry which returned 1.4% over the past year.
Rentabilidad vs. Mercado: S1BA underperformed the German Market which returned -21.6% over the past year.
Volatilidad de los precios
| S1BA volatility | |
|---|---|
| S1BA Average Weekly Movement | 13.5% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Precio estable de las acciones: S1BA's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: S1BA's weekly volatility has decreased from 20% to 13% over the past year, but is still higher than 75% of German stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2006 | 38 | Reenie McCarthy | www.stealthbt.com |
Resumen de fundamentos de Stealth BioTherapeutics Corp
| Estadísticas fundamentales de S1BA | |
|---|---|
| Capitalización bursátil | €23.54m |
| Beneficios(TTM) | -€50.69m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-0.4x
Ratio precio-beneficio (PE)¿Está S1BA sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de S1BA | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$52.53m |
| Beneficios | -US$52.53m |
Últimos beneficios comunicados
Dec 31, 2021
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.71 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | -30.1% |
¿Cómo se ha desempeñado S1BA a largo plazo?
Ver rendimiento histórico y comparativa